Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer
British Journal of Cancer, 2020
Liu S., Shen M., Hsu E., Zhang C., Garcia-Marques F., Nolley R., Koul K., Rice M., Aslan M., Pitteri S., Massie C., George A., Brooks J., Gnanapragasam V., Stoyanova T.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology | Patient Stratification |
Abstract
Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low risk); CPG5 (high risk) and metastatic disease were analysed using Olink Proteomics panels. Tissue validation was performed by immunohistochemistry in a radical prostatectomy cohort (n = 234). We discovered that nine proteins (pleiotrophin (PTN), MK, PVRL4, EPHA2, TFPI-2, hK11, SYND1, ANGPT2, and hK14) were elevated in metastatic PC patients when compared to other groups. PTN levels were increased in serum from men with CPG5 compared to benign and CPG1. High tissue PTN level was an independent predictor of biochemical recurrence and metastatic progression in low- and intermediate-grade disease. These findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation.